Thymosin ¦Á1 Combined With Hepatic Artery Infusion Chemotherapy And Embolization In The Treatment Of Advanced Liver Cancer Clinical Research

Objectives: We study the clinical therapeutic effect and immunological fuction by using transcatheter hepatic arterial infusion chemotherapy and combining lodinated oil embolization and combing thymosin for primary hepatocarcinoma by restropective observation, through detecting immunological fuction of primary hepatocarcinoma, HBVDNA of hepatitis B virus, alpha-fetoprotein and change of carcinoma size under B ultrasound.Mathods: All the patients were confirmed to be primary. Hepatocarcinoma were confirmed with B ultrasound,CT and biopsy or fineneedle aspiration biopsy. All the enrolled cases had complete clinical data eiconographic data and intact laboratory examination. They all had not received radiotherapy in recent four weeks, with no major organs damaged, Karnofsky scores 60. The patients were 30 cases satisfied with those demands, They all were first therapy cases. The patients were randomly divided into interventional therapy group(control group) and interventional therapy combined with thymosin immune group (study group).We observed the effect during the thrapy. In the study, HBVDNA was measured with real time fluorescent quantitative PCR .The level of serum AFP was measured with immunoassay. The carcinoma sizes were compared with B ultrasound before treatment and after treatment,CD4 and CD4/CD8 ratio were measured by fluorescent antibody technique .Results: The CD4 level and CD4/CD8 ratio in HCC patients were lowed than those of healthy persons 。 During the TACE interventional treatment course, In the control group,CD4.CD4/CD8 level decreased during the first course of treatment。 While during the third courses of treatment. No statistical differences were found between pro-treatment and post-treatment. In the study group, no statistical differences were found between pre-treatment and post-treatment about cd4. CD4/CD8 level while CD4.CD4/CD8 level increased significantly during the third courses of treatment.2.In control group, HBVDNA increased during the first course of treatment, but there were no statistical differences. In the study group, no changes were found after the first course of treatment. Amounts of HBV decreased significantly after the third course of treatment. There were statistical differences.3.Alpha-fetoprotein decreased both in control group andstudy group than pro-treatment after the first course of treatment and the third course of treatment* both have statistical differences, so Alpha-fetoprotein could be regarded as an important index in evaluating therapeutic effect.4.There were no differences in effective power through B ultrasound monitoring between the control group and the study group cases after the first course of treatment than pro-treatment. There were differences after the third course of treatment than pro-treatment (p< 0.05)But there were no differences between the two groups. This indicate the two therapy methods were effective, patients could live with tumors.5.There were no differences in live ratio of half year but there were significantly difference of two years and over two years by monitoring between two groups.Conclusion: 1. Transcatheter hepatic arterial infusion chemotherapy combining lodinated oil embolism and combining thymosin for primary hepytocarcinoma could increase patients' immunologic function and long live ratio. 2.Monitoring the HBVDNA amounts combining serum and clinical einocographic could be regarded as an important index in evaluating therapeutic effect.